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SUMMARY
The aim of this study conducted in France was to confirm the efficacy and
safety of the oral administration of carprofen (Rimadyl®) at 4 mg/kg once a
day during four months in the treatment of clinically chronic osteoarthritis in
dogs. One hundred and ten dogs with chronic clinical signs of osteoarthritis
were enrolled. The overall severity of the osteoarthritis condition and the cli-
nical signs of osteoarthritis were assessed using visual analogue scales
(VAS) on days 0, 5, 30, 60, 90 and 120.  During the same visits, owners were
asked to perform their own efficacy assessment through the grading of seven
parameters using categorical scales. Hematological analyses were perfor-
med on days 0 and 120. Clinical blood chemistry evaluations were perfor-
med on days 0, 5, 60 and 120. The percentage of dogs showing a positive
treatment effect increased from 12% on day 5 to 74% on day 120. The mean
VAS scores significantly decreased throughout the study (P ≤ 0.05). Gastro-
intestinal undesirable effects likely to be related to carprofen but with no
harmful consequences were observed in 5% of treated dogs.  No detrimental
effects of the treatment on haematological, renal and hepatic parameters
were observed. These results show that carprofen at 4 mg/kg once daily can
be safely used over a 4 month period in the treatment of osteoarthritis in dogs
and provides a steadily increasing improvement of the clinical signs.
Key-Words : osteoarthritis, carprofen, efficacy, safety,
dog
RÉSUMÉ
Efficacité et innocuité de l’administration orale de carprofène à long
terme dans le traitement de l’arthrose chez les chiens.
L'objectif de cette étude menée en France était de confirmer l'efficacité et
la sécurité d'emploi du carprofène (Rimadyl®) administré par voie orale à la
posologie de 4 mg/kg une fois par jour et pendant quatre mois dans le traite-
ment de l'arthrose accompagnée de signes cliniques chroniques chez les
chiens. Cent dix chiens présentant des signes cliniques chroniques d'arthrose
ont été inclus dans cette étude. La sévérité globale de l'arthrose ainsi que les
signes cliniques d'arthrose ont été évalués en utilisant une échelle analogique
visuelle (EAV) aux jours 0, 5, 30, 60, 90 et 120.  Aux mêmes visites, les pro-
priétaires ont procédé à leur propre évaluation de l'efficacité en quantifiant
sept paramètres sur des échelles qualitatives. Des analyses hématologiques
ont été réalisées aux jours 0 et 120. Des analyses biochimiques sanguines
ont été réalisées aux jours 0, 5, 60 et 120. Le pourcentage de chiens montrant
un effet positif du traitement a augmenté de 12% au jour 5 à 74% au jour
120. Les scores moyens d'EAV ont diminué de manière significative durant
l'étude (P ≤ 0.05).  Des effets indésirables gastro-intestinaux probablement
liés au carprofène mais sans conséquences dommageables ont été observés
chez 5% des chiens traités.  Aucun effet  préjudiciable du traitement n'a été
observé sur les paramètres hématologiques, rénaux et hépatiques. Ces résul-
tats montrent que le carprofène administré quotidiennement à la posologie de
4 mg/kg peut être utilisé sans risque sur une période de quatre mois dans le
traitement de l'arthrose chez les chiens tout en améliorant progressivement
les signes cliniques.
Mots-Clés : arthrose, carprofène, efficacité, sécurité
d’emploi, chien
Introduction
Osteoarthritis is a common concern for owners of old dogs
but it has also been estimated that some forms of osteo-
arthritis affect more than 20% of dogs which are more than
one year old [5]. Osteoarthritis is a slowly progressive degen-
erative disease of synovial joints characterized by pain,
disability, destruction of cartilage, and bony remodelling [6].
As it is a chronic disease that cannot be cured, it requires
long-term care. The current trend is to promote the contin-
uous use of non steroidal anti-inflammatory drugs (NSAIDs)
over long periods because of their ability to reduce joint pain
and decrease synovitis [6]. However several NSAIDs used in
veterinary medicine have been involved in gastro-intestinal,
renal and haematological adverse effects as well as in carti-
lage destruction in cases of prolonged administration [4].
Carprofen (Rimadyl®; Pfizer) is a member of the group of
NSAIDs. It is a carboxylic acid belonging to the subclass of
arylpropionic acids which exerts its anti-inflammatory and
analgesic effects primarily by inhibiting the cyclooxygenase
enzyme and blocking the production of prostaglandins [3].
Carprofen is approved for the long-term treatment of osteo-
arthritis in dogs in most European countries.
The safety margin of carprofen was found to be relatively
wide compared with other NSAIDs in toxicological studies
[4]. In addition, daily administrations of carprofen at 4 mg/kg
did not have any deleterious effect on the cartilage structure
in several in vitro and in vivo studies.  Instead, the latter
studies showed a potential beneficial effect [1, 11, 2]. At ther-
apeutic concentrations in dogs, carprofen increases the
synthesis of proteoglycans in the osteoarthitic cartilage [1,
11, 2]. In experimentally induced osteoarthritis in dogs,
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carprofen at 4 mg/kg once daily for two months reduces the
progression of morphologic changes of the joint in compar-
ison with non-treated dogs [8]. The purpose of the present
multi-centre study, which took place in France and involved
16 veterinary clinics, was to confirm the efficacy and safety
of the continuous use of Rimadyl® tablets over a four month
period in the treatment of clinically chronic cases of osteo-
arthritis in dogs.
Materials and methods
ANIMALS
One hundred and ten household dogs of 47 different breeds
(Labrador retriever (19), German shepherd (18), Brittany (8),
Poodle (5), Collie (5), Beauceron (4), Beagle (3) and other
breeds represented by one or two dogs) were selected from
the clinic population presented to each investigator. Their
mean age was 9.3 years, and their mean body weight 30.3 kg.
The study population consisted of 49% entire males, 5%
neutered males, 32% entire females and 15% spayed females.
All enrolled animals displayed chronic clinical signs of
osteoarthritis including but not limited to: lameness (unilat-
eral or bilateral), stiffness when standing up or lying down,
muscle atrophy linked to the decreased use of the limb,
decreased range of motion of the affected joint, pain on
manipulation of the joint, crepitus on movement of the joint
or signs more pronounced with cold and wet climatic condi-
tions. These signs had been continuously observed for more
than two weeks or recurrently for more than three months.
In dogs presenting with multiple joints affected with
osteoarthritis, only the one displaying the most severe clin-
ical signs was selected and considered for the different
assessments required by the study. Joints selected for the
assessments were as follows:  hip (40%), knee (24%), elbow
(18%), scapulo-humeral joint (6%), carpus (6%) and tarsus
(6%). For 73% of the selected joints, osteoarthritis was
secondary to another cause. Dysplasia was the most frequent
origin (45% of the cases), followed by the rupture of the
cruciate ligament (20% of the cases). All other origins were
less frequent and below 8%. 
For each dog, the diagnosis of osteoarthritis was confirmed
by a radiographic evaluation of the selected joint, showing
amongst others the presence of new bone proliferation,
decreased joint space (joint degeneration) and increased
density of subchondral bone.
The dogs with lameness related to a neoplasic condition, a
primary neurologic disorder, an immunologic disorder or an
infection were not enrolled in the study.  At enrolment, the
selected animals hadn’t had any surgery on the affected joint
within the last month prior to inclusion.  They had not
received intra-articular injections of any type within the last
month prior to inclusion, systemic anti-inflammatory drugs
(i.e. NSAID’s or short acting corticoids) within the last 7
days prior to inclusion or repository anti-inflammatory drugs
within the last 30 days prior to inclusion.  They did not suffer
from any condition that would have required surgical inter-
vention in the next 4 months following inclusion, or any
concurrent disease or medication that could interfere with the
carprofen treatment.  The dogs presenting with contra-indica-
tions to carprofen administration were not included in the
study either.
TREATMENT
Two commercial formulations of carprofen were used in
this study (Rimadyl® Tablets 20 mg and Rimadyl® Tablets
50 mg; Pfizer). The day treatment commenced was defined as
day 0. Treatment was administered once a day until the last
scheduled visit on day 120. Rimadyl® tablets were broken to
the nearest half tablet (score of the tablet) to achieve the
desired dose of approximately 4 mg/kg. Actual dosing was
recorded by the animal’s owner on a daily basis.
CLINICAL FOLLOW-UP
Apart from a few exceptions, study animals were examined
on day 0, on day 5 ± 2 days and on days 30, 60, 90 and 120 ±
4 days and, when relevant, on the day of withdrawal from the
study.  
At each visit, a physical examination was performed
including the assessment of rectal temperature, pulse, respi-
ratory rate and body weight. The severity of the osteoarthritis
condition of the selected joint was scored by the investigator
and based on the assessment of four clinical parameters using
Visual Analogue Scales (VAS) of 100 mm. The investigator
drew a vertical bar on the scale, between 0 mm (minimum
severity) and 100 mm (maximum severity) according to his/
her own judgement of the severity of each of the three
following clinical parameters: lameness, limitation of joint
movement, pain on movement. Then, the investigator
assessed the overall severity of the condition summarising
the three above parameters (Table 1). A correspondence
between scale zones and clinical descriptions for every
parameter enabled consistency of scoring between investiga-
tors and the transformation of scores into grades, in order to
describe the dog in a qualitative way (frequency by clinical
grade for each parameter). The dogs’ condition was also
assessed by the owner at each observation point. The owner
assessment was based on the grading of seven parameters
including the dog’s ability for standing up or lying down,
walking, running, jumping (up and down), going upstairs or
downstairs, playing or taking exercise as well as the influence
of climatic condition (Table 2).  
 Animals showing a greater “overall severity of the condi-
tion” score than on day 0 after a minimum of 5 days of
therapy were considered to show worsening of the osteo-
arthritis condition, and were therefore removed from the
study. In case of suspected adverse reactions to carprofen, the
treatment was either suspended for a few days or stopped, at
the investigator’s discretion. Removal from the study due to
any of the reasons above, was considered a treatment failure. 
At each visit, the treatment effect was assessed (Table 3).
At the end of the 4-month study, the overall treatment effi-
cacy compared with day 0 was assessed by both the investi-
MARS07.book  Page 120  Lundi, 26. mars 2007  11:00 11
EFFICACY OF CARPROFEN IN OSTEOARTHRITIS TREATMENT IN DOGS
Revue Méd. Vét., 2007, 158, 03, 119-127
121
gator and the owner according to the following scale:
clinically cured (0), substantially improved (1), moderately
improved (2), slightly improved (3), equal (4) or worse (5).
SAMPLINGS
Blood samples were taken on the day of inclusion and on
days 5, 60, 120 and before any withdrawal from the study.
Hematology (haemoglobin, hematocrit, RBC, WBC
(including WBC differential count), platelet count) was
performed on the day of inclusion, day 120 and before any
removal. Clinical chemistry (total proteins, albumin, urea,
creatinine, alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and serum bile acids) was performed
on the day of inclusion, days 5, 60 and 120 and before any
withdrawal. 
Blood samples were collected, either on a dry tube with a
serum separating gel for clinical chemistry or on an EDTA
tube for haematology, from dogs which had been fasted for at
least 6 hours and at most 12 hours.  Tubes were kept for a
maximum of 3 days between +4 and +8˚C and then sent by
mail to the laboratory at ambient temperature.  All analyses
were performed by the same laboratory.  The blood cell
counts were done using a COULTER T540 model counter in
veterinary mode. The white blood cell differential count was
carried out by counting the various cell types (from 100 cells)
on a smear after colouring. The total protein concentrations
were read on an ATAGO SPR-T2 refractometer. The anal-
yses of the other biochemical parameters were carried out in
liquid chemistry by optical reading of density on a
LABSYSTEM FP9 spectrophotometer.
DATA ANALYSIS
The efficacy and safety of the carprofen long-term treat-
ment were primarily assessed on basis of:
Evolution over time of the treatment effect through the
percentage of patients in the different possible categories of
treatment effect (Table 3).
Evolution over time of the four clinical parameters
assessed by the investigators.
Evolution over time of RBC, WBC, platelets, urea, creati-
nine, ALT and serum bile acids.
All other parameters were considered secondary.
The four clinical parameters assessed by the investigators
and the blood parameters were analyzed using a general
linear repeated measure mixed model analysis of variance,
including the fixed effect of time and the random effects of
block and animal within block where the investigators were
considered as blocks. Fisher’s protected LSD for pairwise
comparisons were performed between every on-treatment
time point (day 5, 30, 60, 90 or 120 visits) and the pre-treat-
ment (day 0 visit) means. 
Scale zone Grade Clinical parameters
0-20
21-40
41-60
61-80
81-100
0
1
2
3
4
Lameness
Walks normally
Slight lameness
Serious lameness
Severe lameness 
Walks on 3 limbs
0-20
21-40
41-60
61-80
81-100
0
1
2
3
4
Limitation of Joint Movement
No limitation of joint movement (0 %)
Mild limitation of joint movement (10-20 %)
Moderate limitation of joint movement (20-30%)
Serious limitation of joint movement (30-50 %)
Severe limitation of joint movement (>50 %)
0-20
21-40
41-60
61-80
81-100
0
1
2
3
4
Pain on movement
No pain on motion of affected joint
Slight pain on motion of affected joint (slightly pulls limb away)
Moderate pain on motion of affected joint (pulls limb away)
Severe pain on motion of affected joint (becomes aggressive)
Refuses to be approached 
0-20
21-40
41-60
61-80
81-100
0
1
2
3
4
Overall Severity of the Condition
Normal Condition
Mild Condition
Moderate Condition
Serious Condition
Severe Condition
TABLE 1. Scoring and grading scale for the assessment of osteoarthritis by investigators
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Results
At each scheduled visit, treatment compliance was
assessed by counting the number of days the treatment had
been taken correctly. A patient was considered as treatment
compliant if the percentage of days with correct dosing (from
day 0) was more than 80% and if there were no more than 2
days of incorrect dosing for every seven-day sequence from
the previous to the current scheduled visit. Following this
definition, more than 88% of the dogs were treatment
compliant throughout the study. 
EFFICACY
From the 110 dogs enrolled into the study, 97 completed
the study, three were considered treatment failures (two due
to suspected adverse reactions (gastro-enteritis) on days 5
and 57 and one due to worsening of the osteoarthritis condi-
tion on day 93) and were therefore withdrawn from the study
and ten were withdrawn for other reasons than treatment
failure. 
A continuous and steady improvement of clinical signs
associated with the osteoarthritis condition, as the carprofen
Grade Parameters
0
1
2
3
4
Standing up or lying down
My dog stands up or lies down without difficulty
My dog sometimes shows some difficulty to stand up or to lie down especially after prolonged rest
My dog often shows some difficulty to stand up or to lie down
My dog permanently shows great difficulty to stand up or to lie down
My dog refuses to stand up or to lie down
0
1
2
3
4
Walking
My dog walks normally
My dog shows stiffness when walking ; this vanishes after some paces
My dog shows permanent stiffness when walking  and/or slight lameness
My dog permanently shows slight lameness
My dog permanently shows severe lameness
0
1
2
3
4
Running
My dog runs without difficulty
My dog shows slight lameness after rest, disappearing after a few paces
My dogs shows lameness after prolonged physical exercise 
My dog shows permanent lameness, when running
My dog refuses to run or runs on 3 limbs
0
1
2
3
4
Jumping up and down (into or from a car, for example)
My dog jumps enthusiastically
My dog sometimes shows some difficulty to jump
My dog permanently shows some difficulty to jump
My dog permanently shows a lot of difficulty to jump
My dog refuses to jump
0
1
2
3
4
Going upstairs or downstairs
My dog easily goes upstairs or downstairs
My dog sometimes shows some difficulty to go upstairs or downstairs
My dog often shows some difficulty to go upstairs or downstairs
My dog permanently shows a lot of difficulty to go upstairs or downstairs
My dog refuses to go upstairs or downstairs
0
1
2
3
4
Playing or doing physical exercise
My dog is able to play or do physical exercise for a long time without showing exaggerated tiredness
My dog is able to play or do physical exercise for a long time but sometimes shows some pain or great tiredness
My dog plays or does physical exercise only for a short period of  time, after which he seems not to take further 
interest in playing or doing exercise
My dog is reluctant to play or to do physical exercise; he gets rapidly tired and/or shows evident pain
My dog refuses to play or to do exercise
0
1
Influence of climatic conditions
Climatic conditions have no influence on clinical condition of my dog 
My dog seems to have difficulty to move when it is cold and wet
TABLE 2. Grading scale for the assessment of osteoarthritis by owners
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treatment continued, was seen. Thus, the percentage of dogs
with a positive treatment effect increased steadily from 12%
on day 5 to 74% on day 120. Similarly, the percentage of
dogs with a neutral treatment effect steadily decreased from
86% on day 5 to 22% on day 120 (Figure 1). 
As a result of the prolonged use of carprofen, the mean
overall VAS scores of the four clinical parameters assessed by
the investigators continuously and significantly decreased
between day 0 and days 5, 30, 60, 90 and 120 (P ≤ 0.05) (Figure
2). VAS scores of individual dogs showed the same trend.
With the four clinical parameters transformed into grades,
the positive effect of the carprofen treatment was also
obvious, when the distribution of dogs in the different grades
was compared between day 0 and day 120 (Figure 3).Even
the condition of the most severely affected animals (grade 4)
quickly improved with the carprofen treatment.
The owners also observed a continuous and steady
improvement of the parameters, as the carprofen treatment
went on (Figure 4).Overall, this improvement was compa-
rable to that observed by the investigators. The effect of
carprofen on the sensitivity to climatic conditions was not as
noticeable as on other parameters. The percentage of animals
in grade 0 (no influence of climatic conditions) only
increased from 44% on day 0 to 59% on day 120.
According to the assessment of the overall efficacy made
by the investigators, 98% of the dogs completing the study
were deemed improved (Figure 5) whilst no improvement
was reported in only 2% of them.  It should be reminded that
only one and two dogs did not complete the study because of
worsening of the osteoarthritis condition or Suspected
Adverse Reactions before study end, respectively.  The
assessment of overall efficacy made by the owners was very
close to the investigators’ assessment.    
Categories 
Treatment in Progress :
Any animal that is still in the study at 
the time of observation
Positive Treatment Effect : 
Any animal with an “Overall Severity of the Condition” score reduction > 20 mm to 
that observed at Day 0 visit.
Neutral Treatment Effect :
Any animal with an “Overall Severity of the Condition” score reduction ≤ 20 mm to 
that observed at Day 0 visit.
Unknown :
No information available to estimate the treatment effect.
Treatment Failure 
Due to worsening of the osteoarthritis condition :
Any animal that has been removed from the study by the investigator due to an 
“Overall Severity of the Condition” score greater than that observed at Day 0 visit.
Due to suspected adverse reaction related to carprofen :
Any animal that has been removed from the study by the investigator due to a side 
effect/suspected adverse reaction related to carprofen, independently of its score in the 
‘Overall Severity of the Condition’.
Removal for any other reason than 
Treatment Failure
Animal removed from the study due to concurrent disease, death, absence of follow 
up, etc ...
TABLE 3. Categories of treatment effect 
Figure 1 : Effect of treatment over time
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Figure 2 : Evolution over time of the four clinical parameters scored by investigators (Least square means)
Figure 3 : Evolution over time of the four clinical parameters graded by investigators
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SAFETY
No suspected adverse reactions were reported from 86 out
of the 110 enrolled dogs over the whole study period.
Thirty-four suspected adverse reactions involving 24 dogs
were recorded during the study. Only 11 events involving 5
dogs (5% of all dogs), all described as gastro-intestinal cases,
were judged by the investigators to be related to carprofen.
Only two dogs (2% of all dogs) were withdrawn from the
study because of suspected adverse reactions considered by
the respective investigators to be related to carprofen. These
dogs recovered following normal veterinary care after the
carprofen treatment was stopped and no long-term detri-
mental effects were reported.
No detrimental effects of the prolonged carprofen treat-
ment period on hematological parameters (especially red and
white blood cell counts and platelet counts) were seen, as
shown by similar means and ranges between study start and
study end.  Mean and range values of renal and hepatic
parameters did not substantially change throughout treatment
(Table 4).  The few significant differences with concentra-
tions at day 0 were biologically insignificant. Mean levels of
secondary biochemical parameters remained also unchanged
throughout the study period. 
DISCUSSION
The results of the present study are in accordance with
those of previous studies. Indeed, several controlled (versus
placebo) or uncontrolled studies on long-term use of
carprofen in the treatment of osteoarthritis in dogs have been
conducted over the past years. In a randomized controlled
trial in which carprofen was administered at 2.2 mg/kg twice
a day for 14 days to 36 dogs, Vasseur and others [13] noted
no difference in the results of clinical blood chemistry,
urinalysis or fecal occult blood test between carprofen and
placebo-treated animals. In the same study, the force plate
evaluation showed that a dog treated with carprofen was 3.3
times more likely to have a positive response than a dog
treated with placebo. These proportions were 3.5 and 4.2 for
the investigator and owner clinical evaluations, respectively.
In another randomized controlled study, Holtsinger and
others [3] administered 2.2 mg/kg of carprofen twice a day
for 14 days to 97 dogs. The results showed that dogs treated
Figure 4 : Evolution over time of six parameters assessed by owners
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with carprofen responded favourably to the drug in 79% of
the cases and that they were 24.8 times more likely to receive
a positive evaluation by the veterinarian than those treated
with a placebo. The suspected adverse reactions in this study
were minor, transient and similar in both treatment groups. A
third randomized controlled trial conducted by Moreau and
others [7] involved 17 dogs, which received 2.2 mg/kg twice
a day during 60 days. Ground reaction forces of the arthritic
Figure 5 : Assessment of “overall efficacy” at study end (comparison Day 120 vs Day 0)
 Day 0 Day 5 Day 60 Day 120
PARAMETER Mean Min Max Mean Min Max Mean Min Max Mean Min Max
Urea 
(mmol/L)
7 1.7 20 7
ns
1.7 18 7
ns
1.7 18 7
ns
1.7 18
Creatinine 
(μmol/L)
53 9 141 53
ns
9 132 62* 9 114 62* 18 132
ALT 
(IU/L)
38 2 283 37
ns
1 272 52* 5 324 43
 ns
3 343
Serum Bile Acids 
(μmol/L)
27 5 144 32
ns
5 200 33
ns
5 217 19* 5 89
Total Proteins (g/L) 73 48 92 73 56 94 72 60 94 74 60 92
Albumin 
(g/L)
33 24 50 33 26 46 33 22 50 33 21 41
AST 
(IU/L)
14 1 39 13 1 43 19 2 139 20 3 75
Statistical comparisons were carried out only for Urea, Creatinine, ALT and Serum Bile Acids; ns means not statistically different (P>0.05) from Day 0 visit; 
* means statistically different (P ≤ 0.05) from Day 0 visit.
TABLE 4 : Summary table of biochemical parameters
1	

!$*
 "*
"*
$*
* *
2
(
	
3

	
(
	

4

5.
!%*
#'*
!#*
* *
!+*
2
(
	
3

	
(
	

4

MARS07.book  Page 126  Lundi, 26. mars 2007  11:00 11
EFFICACY OF CARPROFEN IN OSTEOARTHRITIS TREATMENT IN DOGS
Revue Méd. Vét., 2007, 158, 03, 119-127
127
limbs and clinical signs assessed by the investigators were
improved by carprofen; in addition, no changes were seen in
blood and faecal analyses. A survey conducted in France
[10], showed that the clinical signs of osteoarthritis continu-
ously and steadily improved in 337 dogs treated during more
than 2 months with carprofen at 4 mg/kg once a day. A very
low incidence of suspected adverse reactions was observed in
this survey. The most recent study reported by RAEKALLIO
and others [9] concluded that a two-month oral administra-
tion of carprofen at 4 mg/kg once daily in osteoarthritic dogs
was well tolerated.
NSAIDs are widely used in human medicine where their
adverse effects are well known. The assumption that adverse
reactions may increase with the length of NSAID administra-
tion seems to be logical.  However, VALLOT [12] reported
studies in humans showing that the relative risk of suspected
adverse reaction was almost 2 times higher when NSAIDs
were administered for less than 30 days than for longer
periods of administration. Therefore, the risk seemed to reach
its maximum during the initial days of long-term treatment.
The studies on carprofen administration over a period longer
than one month are consistent with the observations reported
in the present study. Thus, the extension of treatment periods
with carprofen is not correlated with a higher incidence of
gastro-intestinal suspected adverse reactions compared to
shorter treatment lengths.
The results of the present study as well as those of previous
studies clearly demonstrate that the long-term administration
of carprofen provides a steadily increasing improvement of
clinical signs of osteoarthritis in dogs and does not result in
an increase of the incidence of suspected adverse reactions.
The risk/benefit ratio of long-term carprofen treatment is
therefore clearly proven to be positive in dogs.
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